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Urocortin 2 (Ucn 2) is a corticotrop releasing factor paralog peptide with many physiological functions and it has 
widespread distribution. There are some data on the cytoprotective effects of Ucn 2, but less is known about its 
neuro- and retinoprotective actions. We have previously shown that Ucn 2 is protective in ischemia-induced retinal 
degeneration. The aim of the present study was to examine the protective potential of Ucn 2 in monosodium-
glutamate (MSG)-induced retinal degeneration by routine histology and to investigate cell-type specific effects by 
immunohistochemistry. Rat pups received MSG applied on postnatal days 1, 5 and 9 and Ucn 2 was injected 
intravitreally into one eye. Retinas were processed for histology and immunocytochemistry after 3 weeks. 
Immunolabeling was determined for glial fibrillary acidic protein, vesicular glutamate transporter 1, protein kinase 
Cα, calbindin, parvalbumin and calretinin. 
Retinal tissue from animals treated with MSG showed severe degeneration compared to normal retinas, but 
intravitreal Ucn 2 treatment resulted in a retained retinal structure both at histological and neurochemical levels: 
distinct inner retinal layers and rescued inner retinal cells (different types of amacrine and rod bipolar cells) could 
be observed. These findings support the neuroprotective function of Ucn 2 in MSG-induced retinal degeneration.
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Since the isolation of corticotrophin-releasing factor (CRF), three mammalian CRF-like 
paralogs have been identified. The name, urocortins (Ucn 1, Ucn 2, Ucn 3), has been chosen 
due to the predicted predominant affinity of these peptides for the CRF2-receptor (CRF2-R). 
Ucn 1 and CRF resemble one another the most and they also bind to CRF1-receptors. Ucn 2 
and Ucn 3 have similar structures and both peptides act as a preferential or selective CRF2-R 
agonists, leading to their designation as the selective CRF2-R agonists. High levels of Ucn 2 
and its receptor have been observed in the heart, lung, muscle, stomach, blood cells, skin, 
placenta and hypothalamus, pituitary and adrenal medulla (14). Not surprisingly, urocortins 
have been proposed to participate in many physiological functions, including effects in the 
nervous system. Regarding neuroprotective functions, Ucn 1 has been shown to protect 
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hippocampal neurons, cerebellar granule cells and to be protective in a model of Parkinson’s 
disease (9, 21, 22). Less is known about the protective functions of urocortins in the retina, 
where the CRF family peptides and their receptors have also been shown in different layers. 
CRF1-R (27, 35–40) and CRF2-R mRNA (10, 11) are also expressed in the retina and CRF-
like immunoreactivity is abundant in GABAergic amacrine and horizontal retinal cells. 
The mammalian retina, as a part of nervous system, is an excellent structure to study the 
effects of different neuropeptides. Glutamate is the main transmitter of the mammalian retina, 
but pathological increase of glutamate levels plays a key role in triggering neuronal damage 
in several retinal diseases (28, 33). Several human pathological conditions such as ischemia 
and some types of glaucoma can be mimicked by experimentally elevating the extracellular 
glutamate concentration or applying its analogues (19, 25, 26, 33). One such agent is 
monosodium glutamate (MSG) the application of which leads to the destruction of the entire 
inner retina (8, 18). We have previously described a model for excitotoxic retinal degeneration 
elicited with high amount of MSG, administered in repetitive and systemic ways: three times 
(postnatal days 1, 5, 9) by subcutaneous injection (32). 
Several agents and conditions have been shown to alleviate degenerative changes caused 
by elevated glutamate levels in the retina, such as NMDA-antagonists (28, 29), pituitary 
adenylate cyclase activating polypeptide (PACAP) (6, 7, 32), diazoxide (3) and environmental 
enrichment (31). We have previously described that Ucn 2 has protective effects in ischemic 
retinal degeneration caused by bilateral common carotid artery occlusion (30). The aim of the 
present study was to investigate whether Ucn 2 applied simultaneously with MSG can reduce 
the damage of retinal structure and different retinal cells. 
Materials and Methods
Newborn Wistar rats were housed under light/dark cycles of 12:12 h. Animal housing, care, 
and application of experimental procedures were in accordance with institutional guidelines 
under approved protocols (BA02/2000-24/2011; University of Pécs). They were injected s.c. 
with physiological saline (n = 8) or 2 mg/g body weight MSG (n = 16) on postnatal days (PD) 
1, 5, and 9. Ucn 2 (2 nmol) in 3 μl phosphate buffered with saline (PBS) solution was injected 
into the right vitreous body after each MSG injection. The left eyes received the same 
volumes of vehicle (PBS) and served as normal eyes. On PD21, animals were killed with an 
overdose of anesthetic. Eyes were immediately dissected in ice-cold PBS and fixed in 4% 
paraformaldehyde solution and retinas were processed for histological analysis as previously 
described (1, 32). Briefly, resin embedded retinal sections (2 μm) were stained with toluidine 
blue. Samples for morphometric measurements derived from at least six tissue blocks 
prepared from at least three animals. Central retinal areas within 1 and 2 mm from the optic 
disc were used for measurements (n = 2–5 measurements from one tissue block). We 
measured: (i) cross-section of the retina from the outer limiting membrane to the inner 
limiting membrane (OLM-ILM); (ii) the width of the outer and inner nuclear and plexiform 
layers (ONL, OPL, INL, IPL); and (iii) the number of cells/100 μm section length in the 
ganglion cell layer (GCL). Results are presented as mean ± SEM. Statistical comparisons 
were made using one-way ANOVA test followed by Tukey-B post hoc analysis 
(GraphPadPrism5).
For immunohistochemistry, after the fixation the tissues were washed in PBS and 
cryoprotected in 10% sucrose for 1 hour, 20% sucrose in PBS overnight at 4 °C. For cryostat 
sectioning, retinas were embedded in tissue-freezing medium (Tissue-Tek, OCT Compound), 
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cut in a cryostat (Leica, Germany) at 10 μm radially. Sections were mounted on chrome-
alum-gelatincoated subbed slides and stored at –20 °C until use. Retinal sections underwent 
immunohistochemical procedure as we previously described (2). Briefly, sections were 
incubated with the primary monoclonal or polyclonal antibody for overnight at room 
temperature. We used the following antibodies: anti-glial fibrillary acidic protein (GFAP; 
rabbit; 1:500; Sigma), anti-vesicular glutamate transporter 1 (VGLUT1; rabbit; 1:500; 
Sigma), anti-protein kinase Cα (PKCα; mouse; 1:200; Chemicon), anti-calbindin (1:1000; 
mouse; Sigma), anti-parvalbumin (1:1000; mouse; Sigma) and anti-calretinin (1:1000; rabbit; 
Chemicon). After several washes in PBS, sections were incubated for 2 h in dark with the 
corresponding secondary antibodies (Alexa Fluor 488 and 568, Invitrogen). Sections were 
then washed in PBS and were coverslipped using Fluoromount-G (Southern Biotech). Digital 
photographs were taken with a Nikon Eclipse 80i microscope equipped with a cooled CCD 
camera. Images were taken with the Spot Basic software package. Photographs were further 
processed with the Adobe Photoshop 7.0 program. Images were adjusted for contrast only, 
aligned, arranged and labeled using the functions of the above program. Images were 
evaluated by an examiner blinded to the experimental treatment.
Results
In saline-treated normal preparations, all the layers characteristic for the mammalian retina 
were well visible (Fig. 1A). Ucn 2 treatments alone had no effect on normal control retinas 
(data and picture not shown). As we have previously described (2, 4, 6, 7, 32), retinal tissue 
from animals treated with MSG showed severe degeneration compared to normal retinas. 
The IPL was markedly shrunk and the INL and GCL were intermingled (Fig. 1B). As a 
consequence, the total thickness of the retina was significantly reduced (Fig. 1D). Intravitreal 
Ucn 2 treatment resulted in a more retained retinal structure (Fig. 1C). The IPL remained 
visible and the INL and GCL were clearly separated (Figs. 1C, D). The number of cells in the 
GCL was significantly less than that of the control retinas. However, Ucn 2 administration 
following MSG treatment did not ameliorate the MSG-induced cell loss in GCL (Fig. 1E). 
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Fig. 1. Microphotographs of representative retinas from control (A), MSG- (B) and MSG+Ucn 2-treated retinas 
(C). Statistical comparison of the thickness of the whole retina and the retinal layers (D) and also the number of 
cells/100 μm ganglion cell layer (GCL) length (E). 
*p < 0.05 compared to control retinas; #p < 0.05 compared to MSG-treated retinas. 
Abbreviations: PL – photoreceptor layer; ONL – outer nuclear layer; OPL – outer plexiform layer; INL – inner 
nuclear layer; IPL – inner plexiform layer; GCL – ganglion cell layer. Scale bar: 20 µm
Glial fibrillary acidic protein (GFAP) is a metabolic stress marker (12, 20) expressed in 
the endfeet of retinal Muller glial cells in control condition (Fig. 2A). The MSG-induced 
elevation of GFAP expression could be detected in the whole glial cell. Massively upregulated 
immunopositivity was found throughout the cell from the OLM to the ILM (Fig. 2B). In Ucn 
2-treated retinas the GFAP levels were reduced (Fig. 2C).
Fig. 2. GFAP-immunoreactivity in the rat retina. 
In control retinas the Muller glial cells showed weak GFAP-immunoreactivity in the GCL and ILM (A). GFAP 
immunopositivity of the Muller glial cells were observed through the whole width of the retina with MSG 
treatment (B). Muller radial fibers appeared less strongly GFAP-positive after Ucn 2 treatment (C). 
Abbreviations: OLM – outer limiting membrane; ILM – inner limiting membrane. Scale bar: 20 µm
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In rat retina, vesicular glutamate transporter 1 (VGLUT1) has been described in the OPL 
and throughout the IPL, consistently with the expected synaptic localization of the protein 
(15). In our normal control preparations, VGLUT-1-immunopositive structures were also 
present in the OPL and IPL, and few VGLUT1-positive cells could be observed in the GCL. 
VGLUT1 staining in the OPL and IPL of the rat retina shows the terminals of photoreceptors 
and bipolar cells, respectively (Fig. 3A). MSG-treated retinas showed severe degeneration 
compared to control retinas. In concert with the histological observation the intermingled 
inner retinal layers expressed substantially reduced VGLUT1-positivity (Fig. 3B). Ucn 2 
treatment led to a nearly normal appearance of VGLUT1-immunoreactivity in retinal 
structures (Fig. 3C). 
Fig. 3. VGLUT1 staining in control (A), MSG- (B) and MSG+Ucn 2-treated retinas (C). VGLUT1 expression 
could be observed in OPL, IPL and GCL of the rat retina. After three times MSG treatment, damage to the bipolar 
cell terminals in the IPL is obvious, Ucn 2 treatment ameliorated the damage of the VGLUT1 expressing 
structures. 
Abbreviations: PL – photoreceptor layer; ONL – outer nuclear layer; OPL – outer plexiform layer; INL – inner 
nuclear layer; IPL – inner plexiform layer; GCL – ganglion cell layer. Scale bar: 20 µm
The presence of protein kinase Cα (PKCα) was detected in the rod bipolar cell population 
in the rat retina (34). The labeled structures were the cell bodies of the INL and cell processes 
extending into the IPL, close to the GCL (Fig. 4A). Differences between control and MSG-
treated retinas were observed in the arborization and the number of rod bipolar cells (Fig. 
4B). Ucn 2 treatment substantially counteracted the MSG-induced changes in PKCα 
immunolabeling (Fig. 4C).
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Fig. 4. Rod bipolar cells revealed by PKCα immunostaining. Control (A), MSG- (B)  
and MSG+3xUcn 2-treated retinas (C). 
Rod bipolar cells are fewer and less strongly stained in MSG-treated tissues (B) than in control (A).  
Ucn 2 treatment resulted in not only protection of the retinal layers, but also retained the density of the 
immunoreactive cells which was similar to that of the control tissue (C). 
Abbreviations: INL – inner nuclear layer; IPL – inner plexiform layer; GCL – ganglion cell layer.  
Scale bar: 20 µm
Ca2+-binding proteins such as calbindin, parvalbumin and calretinin are abundant in 
various layers of the mammalian retina (16, 17). Calbindin immunoreactivity was found in 
the cell bodies and processes of the horizontal cells (Fig. 5A). MSG treatment generated only 
a slight alteration in the pattern of immunoreactivity (Fig. 5B). After Ucn 2 treatment 
immunoreactivity was similar to the control level (Fig. 5C). Parvalbumin immunoreactivity 
was identified in the population of AII glycinergic amacrine cells and in a few ganglion cells 
in control retinas (Fig. 5D). Almost no parvalbumin-positive cells could be detected in MSG-
treated retinas (Fig. 5E). In Ucn 2-treated retinas, the structure was similar to the controls, but 
the IPL was thinner than in the untreated tissue (Fig. 5F). Calretinin-positive cells could be 
found in the subpopulations of inner retinal cell classes, especially in ganglion and amacrine 
cells and their processes in the IPL (Fig. 5G). MSG caused the fusion of the inner retinal 
layers leading to the decreased labeled cell number (Fig. 5H). In most cases, Ucn 2 treatment 
not only resulted in a protection of the retinal layers but it also led to a retained density of the 
immunoreactive cells (Fig. 5I).
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Fig. 5. Ca2+-binding proteins (calbindin, parvalbumin and calretinin) expression in control  
(A, D, G), MSG (B, E, H) and MSG+Ucn 2-treated (C, F, I) groups. 
In control, the calbindin is present in cell bodies and processes of the horizontal cells (A). No difference, only 
minimal decrease in intensity of calbindin staining could be observed after MSG application (B).  
After MSG+Ucn 2 treatment calbindin expressing structures were retained (C). 
Parvalbumin immunohistochemistry labeled numerous AII amacrine cells in the control retina (D). 
Immunoreactivity in the MSG-treated retinas was apparently reduced (E). MSG+Ucn 2-treated retina structure was 
almost similar, but the immunoreactivity seemed weaker than that of the control tissue (F). 
Calretinin is normally present in amacrine and ganglion cells and their projections in the INL, IPL and GCL (G). 
MSG treatment caused the fusion of the inner retinal layers (INL, IPL, GCL) so immunoreactivity seemed weaker, 
and the number of labeled retinal cells decreased (H). Ucn 2 treatment counteracted the MSG-induced changes in 
calretinin-immunolabeling (I). 
Abbreviations: INL – inner nuclear layer; IPL – inner plexiform layer; GCL – ganglion cell layer. Scale bar: 20 µm
Discussion
The members of CRF peptide family and their receptors are found throughout the central 
nervous system, including the retina (21). In the present study we proved that Ucn 2 treatment 
was protective in MSG-induced retinal degeneration, retaining structural integrity of the 
tissue and the neurochemical characteristics of several nerve cell types. 
Urocortins are the ancient paralogs of CRF-Rs (14). In the retina, CRF-like 
immunoreactivity has been described in horizontal, amacrine and ganglion cells and their 
processes (35–39). It has been formerly reported that Ucn 1 confers its neuroprotective 
activity through CRF1-Rs via cAMP-dependent pathways (13). The receptor subtype 
underlying the presently shown retinoprotective action of Ucn 2 remains to be determined. In 
the retina the two CRF receptor subtypes are present at both mRNA and protein levels (10, 
40). Based on the present findings, the relevance of endogenous CRF/Ucns to retinal function 
should be further explored. 
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Retinal MSG excitotoxicity leads to degeneration of cells in all retinal layers through a 
complex mechanism involving apoptosis (23, 24). The inner retinal cells bear functional 
ionotropic glutamate receptors, the potential targets of MSG toxicity. A variety of 
pharmacological approaches has been shown to be protective against MSG-induced damage 
and may be relevant to the protective action of Ucn 2 observed here. The effectiveness of 
these protective agents and altered environments in different retinal degeneration models can 
be compared in the light of the morphometric measurements performed in our previous 
studies. In the case of whole retina thickness and retinal layers, the order of effectiveness is: 
enriched environment > diazoxide > PACAP1-38 = PACAP1-27 > Ucn 2. Considering the 
cell number of ganglion cell layer the rank order is different: enriched environment = 
diazoxide = PACAP1-38 = PACAP1-27 > Ucn 2 (1–7, 29, 30). More investigations are 
needed to clear the receptorial and the effector pathway regulation underlying the effects of 
Ucn 2 exerted in the mammalian retina. Data suggest that Ucn 2 may have protective effects 
through decreasing metabolic stress to the retina, thus reducing cell loss. Whether these 
retinoprotective mechanisms involve inhibition of apoptosis, needs to be clarified in future 
experiments. 
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